December 05, 2019

Trump Administration Faces Resistance From Canada for Drug Importation Plan

The Trump Administration's plan to import pharmaceutical drugs from Canada has faced scrutiny from the Canadian stakeholders who warn that the plan would deplete the country's drug supply and cause shortages. The Trump Administration contends that the plan would decrease costs to American consumers and encourage big pharmaceutical companies to reduce prices to keep up with the influx of Canadian drugs. Canadian patient advocates argue that the importation plan would hurt Canada's drug supply, as the Canadian market already faces challenges in providing adequate supply to its domestic patient population. Canada's support is vitally important if the plan is to succeed.